invivoscribe®

Explore Recent Scientific Contributions Using Invivoscribe's Products

Key opinion leaders across the world have recently published papers that discuss the advantages of using highly sensitive next-generation sequencing (NGS) for Minimal Residual Disease (MRD) testing.

Key Topics Discussed:

- MRD testing for Multiple Myeloma, CLL & AML with NGS
- Transitioning from Capillary Electrophoresis to NGS
- Advantages of using NGS versus Flow Cytometry

Ig Gene Clonality Analysis Using Next-Generation Sequencing for Improved Minimal Residual Disease Detection with Significant Prognostic Value in Multiple Myeloma Patients

Ha, J et al. (2022) *The Journal of Molecular Diagnostics.* 24(1):48-56.

Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

Ho, C et al. (2021) *The Journal of Molecular Diagnostics.* 23(2):181-199.

NGS Analysis of Clonality and Minimal Residual Disease in a Patient with Concurrent Richter's Transformation and CLL/SLL

Kadkol, S S et al. (2021) *Case Reports in Hematology.* 2021:9740281.

Immunoglobulin Gene Rearrangement in Koreans with Multiple Myeloma: Clonality Assessment and Repertoire Analysis Using Next-Generation Sequencing

Kim, M et al. (2021) *PLoS One.* 16(6):e0253541.

Validation of a Next-Generation Sequencing-Based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

Ho, C C et al. (2021) *The Journal of Molecular Diagnostics.* 23(7):805-815.

M-0092 Rev 01 May 2022

Key Publications:

Simple Deep Sequencing-Based Post-Remission MRD Surveillance Predicts Clinical Relapse in B-ALL

Cheng, S et al. (2018) *Journal of Hematology & Oncology.* 11(1):105.

Targeted Deep Sequencing Reveals Clinically Relevant Subclonal IgHV Rearrangements in Chronic Lymphocytic Leukemia

Stamatopoulos, B et al. (2017) *Leukemia.* 31(4):837-845.

A Next-generation Sequencing–Based Assay for Minimal Residual Disease Assessment in AML: Patients with *FLT3*-ITD Mutations

Levis, M J et al. (2018) *Blood Advances.* 2(8):825-831.

Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

Arcila, M E et al. (2018) *The Journal of Molecular Diagnostics.* 21(2):330-342.

Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma

Yao, Q et al. (2019) *Frontiers in Oncology.* 9:449.

None of the claims in the publications have been validated by Invivoscribe or reviewed by a regulatory authority.

About Invivoscribe

If you are interested in more information on how to implement NGS LymphoTrack® Assays for clonality and MRD testing on the Illumina® or Thermo Fisher® platforms used in your laboratory, please contact

inquiry@invivoscribe.com

PRODUCTS
Best-in-Class Assays & Reagents

LABPMM®
Global Clinical Lab Services

PARTNERSHIPS
Accelerate Drug Approvals

BIOINFORMATICS
Software Licensing, & Cloud Services

INTELLECTUAL
Property

invivoscribe®
www.invivoscribe.com

San Diego, California | Munich, Germany | Kawasaki, Japan | Shanghai, China

Distributed by Abacus dx
1800 ABACUS (AUS) 0800 222 170 (NZ) | info@abacusdx.com | www.abacusdx.com

abacus dx